Futaden (lafutidine) / Emcure - LARVOL DELTA

Addition of bedtime lafutidine inhibits nocturnal acid-breakthrough and improves sleep quality in gastroesophageal reflux disease patients on esomeprazole: a randomized controlled trial. (PubMed, Sci Rep) - "Therefore, adding bedtime lafutidine to esomeprazole effectively inhibits nocturnal gastric acid secretion and reduces the incidence of NAB. GERD patients who received lafutidine in addition to esomeprazole achieved a more significant improvement in sleep quality correlated with NAB reduction."

Clinical • Journal • Gastroenterology • Gastroesophageal Reflux Disease

Assessing lafutidine's potential to protect lung cancer patients from chemotherapy-induced neuropathy. (PubMed, Ann Palliat Med) - No abstract available

Journal • Lung Cancer • Oncology • Pain • Solid Tumor

Ranitidine Use and Incident Cancer in a Multinational Cohort. (PubMed, JAMA Netw Open) - "The main exposure was use of ranitidine vs other H2RAs (famotidine, lafutidine, nizatidine, and roxatidine). In this cohort study, ranitidine use was not associated with an increased risk of cancer compared with the use of other H2RAs. Further research is needed on the long-term association of ranitidine with cancer development."

Journal • Endocrine Cancer • Genetic Disorders • Non-melanoma Skin Cancer • Skin Cancer • Solid Tumor • Thyroid Gland Carcinoma

A randomized trial to evaluate the preventive effect of lafutidine on chemotherapy-induced peripheral neuropathy in patients treated with carboplatin and paclitaxel for lung cancer. (PubMed, Ann Palliat Med) - "Although the preventive effect of lafutidine on CIPN could not be demonstrated statistically, lafutidine FACT/GOG-Ntx scores showed a trend toward decreased neurotoxicity as chemotherapy proceeded. More reliable studies using lafutidine on the prevention of CIPN should be conducted."

Journal • Gynecologic Cancers • Lung Cancer • Neuralgia • Oncology • Pain • Solid Tumor

TRANSLATING THE RELATIVE POTENCY OF VONOPRAZAN IN THE MANAGEMENT OF ACID-RELATED DISORDERS: A SYSTEMATIC REVIEW (DDW 2023) - "Addition of adjuvant medication (lafutidine or pirenzepine) with VPZ appeared to enhance potency without significantly increasing gastrin levels...VPZ 20 mg daily appeared to perform similarly to 61.8 mg twice daily omeprazole using previously published formula (Graham CGH 2018). In summary, VPZ provide potent inhibition of intragastric acid as assessed by pH4time, with twice daily VPZ more potent than once daily VPZ and addition of adjuvant medications appearing to enhance gastric acid suppression without significantly increasing gastrin levels. Further investigation into translation of potency of P-CABs into dosage strategies for different gastric acid-related disorders remains to be determined."

Review • Gastroenterology • Gastroesophageal Reflux Disease • GAST

Lafutidine Ameliorates Indomethacin-Induced Small Intestinal Damage in Rats by Modifying the Intestinal Mucosal Barrier, Inflammation, and Microbiota. (PubMed, Pharmacology) - "LAF may protect against NSAID enteropathy via enhancing the intestinal mucosal barrier, inhibiting inflammation, and regulating microbiota."

Journal • Preclinical • Anorexia • Hematological Disorders • Inflammation • Inflammatory Bowel Disease • IL1B • MUC2 • OCLN • TJP1 • TNFA

Effect of Concomitant Lafutidine on Adjuvant S-1 for Head and Neck Cancer: A Comparative Study. (PubMed, Anticancer Res) - "Taking lafutidine during S-1 treatment appeared to reduce gastrointestinal disturbance and increased the S-1 completion rate, improving both progression-free and overall survival as a result."

Clinical • Journal • Gastrointestinal Disorder • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

[VIRTUAL] Changes in the trend of gastrointestinal drugs usage due to ranitidine recall event (ASHP 2020) - "Intravenous (IV) route was available for 3 types of H2RAs (cimetidine, ranitidine, famotidine) and 2 of PPIs (pantoprazole, esomeprazole). H2RA was considered primarily as alternative drug class of ranitidine. Famotidine was the representative drug of a trend change in the post-event period. Lafutidine and esomeprazole were also changed the consumption trend."

Gastrointestinal Disorder

Risk of Cancer in Association with Ranitidine and Nizatidine vs Other H2 Blockers: Analysis of the Japan Medical Data Center Claims Database 2005-2018. (PubMed, Drug Saf) - "We found no evidence that ranitidine/nizatidine is associated with an increased risk of cancer, although further studies with more accurate measurement of exposure, inclusion of older people, and longer follow-up may be needed."

Journal • Oncology

Silk industry waste protein: Isolation, purification and fabrication of electrospun silk protein nanofibers as a possible nanocarrier for floating drug delivery. (PubMed, Nanotechnology) - "Lafutidine (LF) being a good candidate for GRDDS selected as a model drug, which is an excellent proton pump inhibitor, mainly used in the treatment of gastric ulcers...It has shown significant floating time >18 h, about 99±0.58 % floating buoyancy with sustained release up to 24 h. LF-SF-NFs showed good compatibility, entrapment efficiency, antioxidant activity, mucoadhesion strength, enzymatic degradation, and long term stability. Soon, the essential floating and drug release profiles can claim single polymer (SF) based electrospun protein NFs as a possible novel oral nanocarrier for FDDS."

Journal • Peptic Ulcer